Is Aristo Bio-Tech overvalued or undervalued?

As of 19 September 2025, the valuation grade for Aristo Bio-Tech has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a PE ratio of 23.14, a Price to Book Value of 2.52, and an EV to EBITDA of 12.37. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Aristo Bio-Tech's PE ratio is notably lower than UPL's 38.81 and P I Industries' 35.1, both of which are categorized as very expensive. Furthermore, while Aristo's PEG ratio stands at 5.64, it is considerably higher than UPL's 0.20, indicating that Aristo may not be justifying its valuation based on growth expectations. Despite recent stock performance showing a 28.79% return over the past year compared to a -0.35% return for the Sensex, the overall valuation metrics suggest that Aristo Bio-Tech is not a compelling investment at its current price of 137.80.